Regarding the mechanism of action, is the GLP-1RA reducing lymphedema because of the induced weight loss or is there another mechanism at play
In addition to weight loss, Orforglipron is being studied for blood sugar control in type 2 diabetes 2
GHK-Cu supports collagen synthesis, wound healing, and tissue regeneration [7] [8]
- and the same state veterinary licenses
And Eli Lilly is feeling the heat: A spokesperson told Bloomberg that in a major orforglipron trial, 6.2% of placebo patients quit because they were unhappy with their weight loss, and 2.5% sought other ways to drop pounds, which sometimes meant they took different obesity medications
For split dosing, which maintains the same total weekly dose, mathematical models suggest efficacy maintenance of 80% to 95%